These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 31442474)

  • 1. Mechanisms of acquired tumor drug resistance.
    Aleksakhina SN; Kashyap A; Imyanitov EN
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188310. PubMed ID: 31442474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting microRNAs in epithelial-to-mesenchymal transition-induced cancer stem cells: therapeutic approaches in cancer.
    Garg M
    Expert Opin Ther Targets; 2015 Feb; 19(2):285-97. PubMed ID: 25563894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.
    Du B; Shim JS
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27455225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The bad seed: Cancer stem cells in tumor development and resistance.
    Koren E; Fuchs Y
    Drug Resist Updat; 2016 Sep; 28():1-12. PubMed ID: 27620951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EMT, CTCs and CSCs in tumor relapse and drug-resistance.
    Mitra A; Mishra L; Li S
    Oncotarget; 2015 May; 6(13):10697-711. PubMed ID: 25986923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer.
    Suresh R; Ali S; Ahmad A; Philip PA; Sarkar FH
    Adv Exp Med Biol; 2016; 890():57-74. PubMed ID: 26703799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
    Glackin CA
    Enzymes; 2018; 44():83-101. PubMed ID: 30360816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial Mesenchymal Transition in Aggressive Lung Cancers.
    Mittal V
    Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cancer Stem Cells (CSCs) as a Rational Therapeutic Cancer Target, and Screening for CSC-targeting Drugs].
    Mashima T
    Yakugaku Zasshi; 2017; 137(2):129-132. PubMed ID: 28154319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer stem cell (CSC) resistance drivers.
    Najafi M; Mortezaee K; Majidpoor J
    Life Sci; 2019 Oct; 234():116781. PubMed ID: 31430455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways.
    Leon G; MacDonagh L; Finn SP; Cuffe S; Barr MP
    Pharmacol Ther; 2016 Feb; 158():71-90. PubMed ID: 26706243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial-mesenchymal transition in squamous cell carcinoma.
    Geng S; Guo Y; Wang Q; Li L; Wang J
    Arch Dermatol Res; 2013 Jan; 305(1):35-47. PubMed ID: 22740085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications.
    Shibue T; Weinberg RA
    Nat Rev Clin Oncol; 2017 Oct; 14(10):611-629. PubMed ID: 28397828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming.
    Thiagarajan PS; Wu X; Zhang W; Shi I; Bagai R; Leahy P; Feng Y; Veigl M; Lindner D; Danielpour D; Yin L; Rosell R; Bivona TG; Zhang Z; Ma PC
    Oncotarget; 2016 Dec; 7(50):82013-82027. PubMed ID: 27852038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PGE
    Lin MC; Chen SY; He PL; Herschman H; Li HJ
    Int J Cancer; 2018 Sep; 143(6):1440-1455. PubMed ID: 29658109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer.
    Liu J; Chen X; Ward T; Mao Y; Bockhorn J; Liu X; Wang G; Pegram M; Shen K
    Int J Biochem Cell Biol; 2016 Feb; 71():12-23. PubMed ID: 26643609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms promoting physiological cells progression into tumorigenesis.
    Korbut E; Ptak-Belowska A; Brzozowski T
    J Physiol Pharmacol; 2012 Dec; 63(6):565-70. PubMed ID: 23388471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epithelial-to-Mesenchymal Transition: Liaison between Cancer Metastasis and Drug Resistance.
    Du F; Liu H; Lu Y; Zhao X; Fan D
    Crit Rev Oncog; 2017; 22(3-4):275-282. PubMed ID: 29604904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib.
    Hashida S; Yamamoto H; Shien K; Miyoshi Y; Ohtsuka T; Suzawa K; Watanabe M; Maki Y; Soh J; Asano H; Tsukuda K; Miyoshi S; Toyooka S
    Cancer Sci; 2015 Oct; 106(10):1377-84. PubMed ID: 26202045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.
    Ricci F; Fratelli M; Guffanti F; Porcu L; Spriano F; Dell'Anna T; Fruscio R; Damia G
    Oncotarget; 2017 Jan; 8(5):7441-7451. PubMed ID: 26910918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.